Takeda
About Takeda
1537 articles about Takeda
-
In2023，the FDA greenlit55new drugs and 34cell and gene therapies。 Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024。 -
software development jobs in the biopharma industry？ Check out these five top companies hiring life sciences professionals like you。 -
Takeda to Present Oncology Portfolio and Pipeline Data the 2024 ASCO Annual Meeting 5/14/2024 Takeda（TSE:45002/NYSE:TAK）today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology（ASCO）being held May31-June42024，in Chicago，Ill。 -
Takeda on Monday said it is paying AC Immune$100 million upfront for anoption on a Phase Ib/II Alzheimer’s disease candidate that could activate the immune system to clear amyloid beta playques。 -
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Target Amyloid Beta for Alzheimer’s Disease 5/13/2024 Takeda and AC Immune SA announced an exclusive，worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta，including ACI-24.06for the treatment of Alzheimer’s disease。 -
Takeda Lowers Profit Outlook Amid Vyvanse Loss of Exclusivity，Eyes$900M Restructuring in 2024 5/9/2024 Takeda saw a57%drop in profit in its2023fiscal year and has lowered its outlook for the coming fiscal year，mostly driven by increasing generic competition for its ADHD treatment Vyvanse。 -
Takeda Announces FY2023 Full Year Results and FY2024 Outlook，Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion 5/9/2024 Takeda announced financial results for fiscal year2023，delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance at CER，in a year of significant loss-of-exclusivity impact。 -
你要我帮你吗？ Check out these top five companies hiring life sciences professionals like you。 -
Takeda Oncology US Head of Sales，Annette Montandon，discusses how embodying a patient-first approach is key to the success of colorectal cancer drug FRUZAQLA ®。 -
塔克达接收位置检测装置 4/26/2024 Takeda（TSE:45002/NYSE:TAK）today announced that the European Medicines Agency’s（EMA）Committee for Medicinal Products for Human User（CHMP）has recommended the approval of fruquitinib，a selective inhibitor of vascular endothelial growth factor receptors（VEGFR）-1,1， -2and-3 for the treatment of adult patients with previously treated metatic colorectal cancer（mCRC）。 -
Top5远程调整作业 4/25/2024 Looking for remote regulatory jobs in the life sciences industry？ Check out the BioSpace list of the top five jobs that don’t require relocation。 -
Takeda，Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Program 4/22/2024 Takeda Pharmaceutical Company Limited，Astellas Pharma Inc.，and Sumitomo Mitsui Banking Corporation announced that the three companies signed a master agreement on April222024，to establish a joint venture company。 -
Bolstered by its portfolio of“revolutionary”therapies，AbbVie remains the top pharma company in the immunology space，according to anew survey of doctors by ZoomRx。 -
U.S.FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO ® （vedolizumab）for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease 4/18/2024 Takeda（TSE:45002/NYSE:TAK）today announced that the U.S.Food and Drug Administration（FDA）has approved ENTYVIO ® （vedolizumab）subcutaneous（SC）administration for maintenance therapy in adults with moderately to severely active Crohn’s disease（CD）after induction therapy with intravenous（IV）ENTYVIO。 -
Top5 Companies Hiring in San Diego 4/11/2024 Looking fora biopharma job in San Diego？ Check out these top five companies hiring life sciences professionals like you。 -
Takeda Announces New U.S.Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food 4/8/2024 Takeda announced the selection of eight new U.S.non-profit organizations as grant recipients，as part of its$14.6million commitment to its FY2023U.S.Corporate Social Responsibility program。 -
Looking fora biopharma job？ Check out the BioSpace list of 11 top companies hiring life sciences professionals like you。 -
Takeda Announces Approval of ADZY NMA ® Intravenous Injection1500（apadamtase alfa/cinaxadamtase alfa）in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura（cTTP） 3/26/2024 Takeda（TSE:45002/NYSE:TAK）today announced that the Japan ese Ministry of Health，Labour and Welfare has approved the use of ADZYNMA（apadamtase alfa/cinaxadamtase alfa）for the treatment of congenital thrombotic thrombocytopenic purpura（cTTP）for individuals12years of and orage。 -
Takeda on Tuesday secured another label expansion for the kinase inhibitor，this time in the first-line setting for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia。 -
Takeda Announces U.S.FDA Approval of Supplemental New Drug Application（sNDA）for ICLUSIG ® （ponatinib）in Adult Patients with Newly Diagnosed Ph+ALL 3/19/2024 Takeda（TSE:45002/NYSE:TAK）today announced that the U.S.Food and Drug Administration（FDA）has approved the supplemental New Drug Application（sNDA）for ICLUSIG ® （ponatinib）for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia（Ph+ALL）in combination with chemotherapy。